InfraReDx’s Long Road To Commercialization Continues With Latest Financing
This article was originally published in Start Up
InfraReDx raised $25 million in late August, another step in its long journey to change the standard of care for coronary artery disease. With the latest financing, the company has raised some $175 million since its founding in 1998, and although it still has far to go, in that length of time InfraReDx, and an understanding of coronary artery disease, have come a long way.
You may also be interested in...
Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
Boston Scientific signed an agreement with the Japanese guidewire-maker Asahi Intecc to develop a fractional flow reserve wire that Boston seeks to launch as part of its first FFR system next year. Asahi will also provide components to upgrade Boston’s RotaWire atherectomy guidewire.